Nurix Therapeutics, Inc. (NASDAQ:NRIX) is Patient Square Capital LP's 6th Largest Position

Patient Square Capital LP grew its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 37.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 446,296 shares of the company's stock after buying an additional 120,507 shares during the quarter. Nurix Therapeutics makes up 3.1% of Patient Square Capital LP's portfolio, making the stock its 6th largest position. Patient Square Capital LP owned about 0.59% of Nurix Therapeutics worth $8,408,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NRIX. Barclays PLC lifted its stake in Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Franklin Resources Inc. lifted its stake in Nurix Therapeutics by 52.4% in the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock valued at $2,766,000 after purchasing an additional 42,315 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after purchasing an additional 31,352 shares during the last quarter. SG Americas Securities LLC lifted its stake in Nurix Therapeutics by 31.1% in the 4th quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock valued at $567,000 after purchasing an additional 7,141 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Nurix Therapeutics by 21.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock valued at $283,000 after purchasing an additional 2,632 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Stephens reissued an "overweight" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Leerink Partners assumed coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. Royal Bank of Canada increased their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Finally, Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Three research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $488,660.76. The trade was a 14.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,838 shares of company stock worth $221,500. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Stock Up 0.2%

Shares of Nurix Therapeutics stock traded up $0.02 during trading on Monday, reaching $9.58. 166,920 shares of the stock were exchanged, compared to its average volume of 876,472. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The stock's fifty day moving average is $11.07 and its 200 day moving average is $16.80. The firm has a market cap of $730.04 million, a price-to-earnings ratio of -3.33 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the business earned ($0.76) EPS. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.